Document Detail


Topical mitomycin C in the prevention of keloid scar recurrence.
MedLine Citation:
PMID:  15897406     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To assess the ability of mitomycin C to prevent the recurrence of surgically excised keloid scars. Mitomycin C has been successfully used to prevent scar tissue formation at the site of subglottic stenosis in the field of pediatric otolaryngology. It appears that mitomycin C interferes with the ability of fibroblasts to produce a scar without causing changes in epithelialization.
DESIGN: We excised keloid scars from various sites in the head and neck and then applied mitomycin C to the resected bed prior to closure of the wound at a concentration of 0.4 mg/mL for 5 minutes. All patients had multiple keloids and acted as their own control. At 1 month after the procedure both wounds were started on a regimen of triamcinolone acetonide, 40 mg/mL injections, repeated every month for 6 months. At the end of the study, photos and measurements were again taken.
RESULTS: Fifteen patients (13 female and 2 male) ranging in age from 10 to 55 years enrolled in the study. No infections or nonhealing wounds were seen. There was no difference in postoperative pain. Eight patients completed the triamcinolone injections, 5 had fewer than 6 injections, and 2 patients had no steroid injections. Twelve patients completed follow-up and were evaluated for surgical complications and recurrence of the keloids at either site. Two patients had partial postoperative follow-up in person and then completed follow-up via telephone. One patient could not be found for follow-up. Four patients had recurrence of both excised lesions. Ten patients had no recurrence of their keloids at either site.
CONCLUSION: Mitomycin C made no difference in the prevention of keloid recurrence after excision when topically applied.
Authors:
Kenneth W Sanders; Linda Gage-White; Fred J Stucker
Related Documents :
23979846 - Effects of conditions of an experimental model to evaluate methods of electric-fence st...
9386866 - Consistency of patient- and doctor-assessed cosmetic outcome after conservative treatme...
23645406 - Frequently asked questions (faqs) about the gold 2011 assessment proposal of copd.
21559226 - Endoscopic vein harvesting for coronary bypass grafting: a blessing or a trojan horse?
24061346 - Is laparoscopy-assisted total gastrectomy feasible for the treatment of gastric cancer?...
9865196 - Injectable hyaluronic acid gel for soft tissue augmentation. a clinical and histologica...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of facial plastic surgery     Volume:  7     ISSN:  1521-2491     ISO Abbreviation:  Arch Facial Plast Surg     Publication Date:    2005 May-Jun
Date Detail:
Created Date:  2005-05-17     Completed Date:  2005-08-04     Revised Date:  2012-09-24    
Medline Journal Info:
Nlm Unique ID:  100883500     Medline TA:  Arch Facial Plast Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  172-5     Citation Subset:  IM    
Affiliation:
Department of Otolaryngology--Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Adolescent
Adult
Case-Control Studies
Child
Cicatrix, Hypertrophic / prevention & control*
Dose-Response Relationship, Drug
Drug Administration Schedule
Ear, External
Female
Follow-Up Studies
Humans
Keloid / drug therapy*,  pathology,  surgery
Male
Middle Aged
Mitomycin / therapeutic use*
Neck
Recurrence / prevention & control
Retrospective Studies
Risk Assessment
Severity of Illness Index
Treatment Outcome
Chemical
Reg. No./Substance:
50-07-7/Mitomycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Modulation of wound response and soft tissue ingrowth in synthetic and allogeneic implants with plat...
Next Document:  The extended columellar strut-tip graft.